Changes in autofluorescence based organoid model of muscle invasive urinary bladder cancer.

Scott Palmer,Karina Litvinova,David Mcgloin,Stewart Fleming,Andrey Dunaev,Ghulam Nabi

doi:10.1364/boe.7.001193

Abstract

Muscle invasive urinary bladder cancer is one of the most lethal cancers and its detection at the time of transurethral resection remains limited and diagnostic methods are urgently needed. We have developed a muscle invasive transitional cell carcinoma (TCC) model of the bladder using porcine bladder scaffold and the human bladder cancer cell line 5637. The progression of implanted cancer cells to muscle invasion can be monitored by measuring changes in the spectrum of endogenous fluorophores such as reduced nicotinamide dinucleotide (NADH) and flavins. We believe this could act as a useful tool for the study of fluorescence dynamics of developing muscle invasive bladder cancer in patients.Published by The Optical Society under the terms of the Creative Commons Attribution 4.0 License. Further distribution of this work must maintain attribution to the author(s) and the published article’s title, journal citation, and DOI.

Highlights

Carcinoma of the urinary bladder is one of the most common urological cancers (4th most frequent malignant disease in men and 7th most frequent in women)
We have developed a muscle invasive transitional cell carcinoma (TCC) model of the bladder using porcine bladder scaffold and the human bladder cancer cell line 5637
The progression of implanted cancer cells to muscle invasion can be monitored by measuring changes in the spectrum of endogenous fluorophores such as reduced nicotinamide dinucleotide (NADH) and flavins

Summary

Introduction

Carcinoma of the urinary bladder is one of the most common urological cancers (4th most frequent malignant disease in men and 7th most frequent in women). In 75–85% of these the cancer does not infiltrate into deeper muscle, i.e. it is carcinoma in situ (CIS), stage Ta/T1 (non-invasive) on first diagnosis; 50–70% of these patients presenting with superficial (non-muscle invasive) stages have one or several recurrences after the initial treatment, and in ≈15% there is disease progression [1]. Sensitivity and specificity of current cystoscopy and urinary biomarkers including cytology are far from satisfactory, leading to use of invasive cystoscopy as a follow-up investigation. The high rates of recurrence in non-muscle invasive urinary bladder cancer and its progression make it one of the most expensive cancers to treat on a per patient basis [2,3,4]. It is clear that something must be done to balance this

Methods

Results

Conclusion